{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:30:59Z","timestamp":1793640659227,"version":"4.5.1"},"reference-count":112,"publisher":null,"issue":"11","license":[{"start":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T00:00:00Z","timestamp":1766880000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/cardio.elpub.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>Despite significant advances in pharmacological, interventional, and surgical treatments for cardiovascular diseases (CVDs) in recent decades, it appeared that the effectiveness of standard treatments has reached a ceiling, and growing attention has been paid to the regulation of inflammation. Immune inflammation is a key component in the pathogenesis of atherosclerosis and its complications, cardiac arrhythmias, and heart failure, but it is also an integral part of tissue regeneration. Consistently, the indiscriminate use of various anti-inflammatory agents with pronounced immunosuppressive properties has failed to demonstrate benefits in heart disease. Numerous studies, including long-term ones, have demonstrated that colchicine remains an anti-inflammatory drug that is not associated with the development of iatrogenic immunodeficiency or increased cardiovascular mortality. Considering this, as well as the effects of colchicine on the immune system components involved in the pathophysiology of CVD, its short half-life, its century-long history of use in rheumatology, and the fact that colchicine is \u201cfamiliar\u201d to cardiologists from the experience of treatment of pericarditis, colchicine appears the most promising and safe for use in common cardiology practice. However, the use of immunomodulators requires a better understanding of the pathophysiology of inflammation, differentiating physiological and excessive inflammation, and the risks associated with impaired endogenous defense. Therefore, colchicine and other immunosuppressants, as distinct from acetylsalicylic acid, cannot be prescribed for formal indications. To define more clearly the patient groups most likely to benefit from colchicine, further research, new diagnostic methods, and the opinion of a cardiologist are needed. This review includes clinical studies, abstracts, and meta-analyses published online with no publication date restrictions up to July 2025. The PubMed, ScienceDirect, Google Scholar, and CENTRAL databases were used, in which 520 literature sources were reviewed describing the clinical efficacy of colchicine drugs and the heterogeneity of its effects in different treatment regimens for various CVDs.<\/jats:p>\n                  <jats:p>\u00a0<\/jats:p>","DOI":"10.18087\/cardio.2025.11.n3016","type":"journal-article","created":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T16:55:48Z","timestamp":1766940948000},"page":"101-111","source":"Crossref","is-referenced-by-count":2,"title":["Colchicine in Cardiology Practice. Mechanisms of Influence on the Cardiovascular System, Use in the Treatment of Pericarditis and Ischemic Heart Disease"],"prefix":"10.68900","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7858-7820","authenticated-orcid":true,"given":"Z. N.","family":"Sukmarova","sequence":"first","affiliation":[{"name":"Nasonova Research Institute of Rheumatology, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. B.","family":"Simonenko","sequence":"additional","affiliation":[{"name":"Branch of the Kirov Military Medical Academy, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2025,12,28]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Nasonov E.L., Drapkina O.M. Colchicine: Repositioning an \u201cancient\u201d medicine in the 21st century. Rheumatology Science and Practice. 2024;62(5):445\u201364. DOI: 10.47360\/1995-4484-2024-445-464","DOI":"10.47360\/1995-4484-2024-445-464"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C et al. Chronic inflammation in the etiology of disease across the life span. Nature Medicine. 2019;25(12):1822\u201332. DOI: 10.1038\/s41591-019-0675-0","DOI":"10.1038\/s41591-019-0675-0"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524\u201333. DOI: 10.1038\/s41586-021-03392-8","DOI":"10.1038\/s41586-021-03392-8"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Roubille F, Kritikou E, Busseuil D, Barrere-Lemaire S, Tardif J-C. Colchicine: An Old Wine in a New Bottle? Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry. 2013;12(1):14\u201323. DOI: 10.2174\/1871523011312010004","DOI":"10.2174\/1871523011312010004"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Hartung EF. History of the Use of Colchicum and related Medicaments in Gout; with suggestions for further research. Annals of the Rheumatic Diseases. 1954;13(3):190\u2013200. DOI: 10.1136\/ ard.13.3.190","DOI":"10.1136\/ard.13.3.190"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Imazio M, Agrimi C, Cescon L, Panzolli G, Collini V, Sinagra G. Colchicine for the treatment of the spectrum of cardiovascular diseases: current evidence and ongoing perspectives. Journal of Cardiovascular Medicine. 2024;25(9):653\u201363. DOI: 10.2459\/JCM.0000000000001647","DOI":"10.2459\/JCM.0000000000001647"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Deftereos SG, Beerkens FJ, Shah B, Giannopoulos G, Vrachatis DA, Giotaki SG et al. Colchicine in Cardiovascular Disease: In-Depth Review. Circulation. 2022;145(1):61\u201378. DOI: 10.1161\/CIRCULATIONAHA.121.056171","DOI":"10.1161\/CIRCULATIONAHA.121.056171"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Angelidis C, Kotsialou Z, Kossyvakis C, Vrettou A-R, Zacharoulis A, Kolokathis F et al. Colchicine Pharmacokinetics and Mechanism of Action. Current Pharmaceutical Design. 2018;24(6):659\u201363. DOI: 10.2174\/1381612824666180123110042","DOI":"10.2174\/1381612824666180123110042"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Zhang F, He Q, Qin CH, Little PJ, Weng J, Xu S. Therapeutic potential of colchicine in cardiovascular medicine: a pharmacological review. Acta Pharmacologica Sinica. 2022;43(9):2173\u201390. DOI: 10.1038\/s41401-021-00835-w","DOI":"10.1038\/s41401-021-00835-w"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nature Reviews Immunology. 2016;16(7):407\u201320. DOI: 10.1038\/nri.2016.58","DOI":"10.1038\/nri.2016.58"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nature Reviews Rheumatology. 2019;15(10):612\u201332. DOI: 10.1038\/s41584-019-0277-8","DOI":"10.1038\/s41584-019-0277-8"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357\u201361. DOI: 10.1038\/nature08938","DOI":"10.1038\/nature08938"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Broderick L, Hoffman HM. IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. Nature Reviews Rheumatology. 2022;18(8):448\u201363. DOI: 10.1038\/s41584-022-00797-1","DOI":"10.1038\/s41584-022-00797-1"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Toldo S, Abbate A. The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases. Nature Reviews Cardiology. 2024;21(4):219\u201337. DOI: 10.1038\/s41569-023-00946-3","DOI":"10.1038\/s41569-023-00946-3"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Mauro AG, Bonaventura A, Vecchi\u00e9 A, Mezzaroma E, Carbone S, Narayan P et al. The Role of NLRP3 Inflammasome in Pericarditis: Potential for therapeutic approaches. JACC: Basic to Translational Science. 2021;6(2):137\u201350. DOI: 10.1016\/j.jacbts.2020.11.016","DOI":"10.1016\/j.jacbts.2020.11.016"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Vecchi\u00e9 A, Del Buono MG, Chiabrando GJ, Dentali F, Abbate A, Bonaventura A. Interleukin-1 and the NLRP3 Inflammasome in Pericardial Disease. Current Cardiology Reports. 2021;23(11):157. DOI: 10.1007\/s11886-021-01589-x","DOI":"10.1007\/s11886-021-01589-x"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Nasonov E.L., Sukmarova Z.N., Popkova T.V., Belov B.S. Problems of immunopathology and prospects for pharmacotherapy of idiopathic recurrent pericarditis: Using an interleukin 1 inhibitor (Anakinra). Rheumatology Science and Practice. 2023;61(1):47\u201361. DOI: 10.47360\/1995-4484-2023-47-61","DOI":"10.47360\/1995-4484-2023-47-61"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Potere N, Abbate A, Kanthi Y, Carrier M, Toldo S, Porreca E et al. Inflammasome Signaling, Thromboinflammation, and Venous Thromboembolism. JACC: Basic to Translational Science. 2023;8(9):1245\u201361. DOI: 10.1016\/j.jacbts.2023.03.017","DOI":"10.1016\/j.jacbts.2023.03.017"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Dobrev D, Heijman J, Hiram R, Li N, Nattel S. Inflammatory signalling in atrial cardiomyocytes: a novel unifying principle in atrial fibrillation pathophysiology. Nature Reviews Cardiology. 2023;20(3):145\u201367. DOI: 10.1038\/s41569-022-00759-w","DOI":"10.1038\/s41569-022-00759-w"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Reina-Couto M, Pereira-Terra P, Quelhas-Santos J, Silva-Pereira C, Albino-Teixeira A, Sousa T. Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets. Frontiers in Physiology. 2021;12:746494. DOI: 10.3389\/fphys.2021.746494","DOI":"10.3389\/fphys.2021.746494"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Vora SM, Lieberman J, Wu H. Inflammasome activation at the crux of severe COVID-19. Nature Reviews Immunology. 2021;21(11):694\u2013703. DOI: 10.1038\/s41577-021-00588-x","DOI":"10.1038\/s41577-021-00588-x"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Abideen ZU, Pathak DR, Sabanci R, Manu M, Abela GS. The effect of colchicine on cholesterol crystal formation, expansion and morphology: a potential mechanism in atherosclerosis. Frontiers in Cardiovascular Medicine. 2024;11:1345521. DOI: 10.3389\/fcvm.2024.1345521","DOI":"10.3389\/fcvm.2024.1345521"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Schwarz N, Fernando S, Chen Y, Salagaras T, Rao SR, Liyanage S et al. Colchicine exerts anti\u2010atherosclerotic and -plaque\u2010stabilizing effects targeting foam cell formation. The FASEB Journal. 2023;37(4):e22846. DOI: 10.1096\/fj.202201469R","DOI":"10.1096\/fj.202201469R"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Zuriaga MA, Yu Z, Matesanz N, Truong B, Ramos-Neble BL, Asensio-L\u00f3pez MC et al. Colchicine prevents accelerated atherosclerosis in TET2-mutant clonal haematopoiesis. European Heart Journal. 2024;45(43):4601\u201315. DOI: 10.1093\/eurheartj\/ehae546","DOI":"10.1093\/eurheartj\/ehae546"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Meyer-Lindemann U, Mauersberger C, Schmidt A-C, Moggio A, Hinterdobler J, Li X et al. Colchicine Impacts Leukocyte Trafficking in Atherosclerosis and Reduces Vascular Inflammation. Frontiers in Immunology. 2022;13:898690. DOI: 10.3389\/fimmu.2022.898690","DOI":"10.3389\/fimmu.2022.898690"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Demidowich AP, Levine JA, Apps R, Cheung FK, Chen J, Fantoni G et al. Colchicine\u2019s effects on metabolic and inflammatory molecules in adults with obesity and metabolic syndrome: results from a pilot randomized controlled trial. International Journal of Obesity. 2020;44(8):1793\u20139. DOI: 10.1038\/s41366-020-0598-3","DOI":"10.1038\/s41366-020-0598-3"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Cimmino G, Tarallo R, Conte S, Morello A, Pellegrino G, Loffredo FS et al. Colchicine reduces platelet aggregation by modulating cytoskeleton rearrangement via inhibition of cofilin and LIM domain kinase 1. Vascular Pharmacology. 2018;111:62\u201370. DOI: 10.1016\/j.vph.2018.09.004","DOI":"10.1016\/j.vph.2018.09.004"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Shah B, Allen N, Harchandani B, Pillinger M, Katz S, Sedlis SP et al. Erratum to: Effect of Colchicine on Platelet-Platelet and Platelet-Leukocyte Interactions: a Pilot Study in Healthy Subjects. Inflammation. 2016;39(1):501\u2013501. DOI: 10.1007\/s10753-015-0266-2","DOI":"10.1007\/s10753-015-0266-2"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Cirillo P, Taglialatela V, Pellegrino G, Morello A, Conte S, Di Serafino L et al. Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel. Journal of Thrombosis and Thrombolysis. 2020;50(2):468\u201372. DOI: 10.1007\/s11239-020-02121-8","DOI":"10.1007\/s11239-020-02121-8"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Opstal TSJ, Hoogeveen RM, Fiolet ATL, Silvis MJM, The SHK, Bax WA et al. Colchicine Attenuates Inflammation Beyond the Inflammasome in Chronic Coronary Artery Disease: A LoDoCo2 Proteomic Substudy. Circulation. 2020;142(20):1996\u20138. DOI: 10.1161\/CIRCU-LATIONAHA.120.050560","DOI":"10.1161\/CIRCULATIONAHA.120.050560"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Silvis MJM, Fiolet ATL, Opstal TSJ, Dekker M, Suquilanda D, Zivkovic M et al. Colchicine reduces extracellular vesicle NLRP3 inflammasome protein levels in chronic coronary disease: A LoDoCo2 biomarker substudy. Atherosclerosis. 2021;334:93\u2013100. DOI: 10.1016\/j.atherosclerosis.2021.08.005","DOI":"10.1016\/j.atherosclerosis.2021.08.005"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez GJ, Robertson S, Barraclough J, Xia Q, Mallat Z, Bursill C et al. Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome. Journal of the American Heart Association. 2015;4(8):e002128. DOI: 10.1161\/JAHA.115.002128","DOI":"10.1161\/JAHA.115.002128"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Suryono S, Rohman MS, Widjajanto E, Prayitnaningsih S, Wihastuti TA, Oktaviono YH. Effect of Colchicine in reducing MMP-9, NOX2, and TGF- \u03b21 after myocardial infarction. BMC Cardiovascular Disorders. 2023;23(1):449. DOI: 10.1186\/s12872-023-03464-9","DOI":"10.1186\/s12872-023-03464-9"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Cronstein BN, Molad Y, Reibman J, Balakhane E, Levin RI, Weissmann G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. Journal of Clinical Investigation. 1995;96(2):994\u20131002. DOI: 10.1172\/JCI118147","DOI":"10.1172\/JCI118147"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Tan Y, Bao X, Li Y, Song G, Lu H, Sun X et al. Colchicine Attenuates Microvascular Obstruction after Myocardial Ischemia-Reperfusion Injury by Inhibiting the Proliferation of Neutrophil in Bone Marrow. Cardiovascular Drugs and Therapy. 2025;39(2):259\u201373. DOI: 10.1007\/s10557-023-07528-y","DOI":"10.1007\/s10557-023-07528-y"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Vaidya K, Tucker B, Kurup R, Khandkar C, Pandzic E, Barraclough J et al. Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. Journal of the American Heart Association. 2021;10(1):e018993. DOI: 10.1161\/JAHA.120.018993","DOI":"10.1161\/JAHA.120.018993"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Xu J, Zhou Z, Zheng Y, Yang S, Huang K, Li H. Roles of inflammasomes in viral myocarditis. Frontiers in Cellular and Infection Microbiology. 2023;13:1149911. DOI: 10.3389\/fcimb.2023.1149911","DOI":"10.3389\/fcimb.2023.1149911"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Chin C-G, Chen Y-C, Lin F-J, Lin Y-K, Lu Y-Y, Cheng T-Y et al. Targeting NLRP3 signaling reduces myocarditis-induced arrhythmogenesis and cardiac remodeling. Journal of Biomedical Science. 2024;31(1):42. DOI: 10.1186\/s12929-024-01032-7","DOI":"10.1186\/s12929-024-01032-7"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Bracey NA, Beck PL, Muruve DA, Hirota SA, Guo J, Jabagi H et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin\u20101\u03b2. Experimental Physiology. 2013;98(2):462\u201372. DOI: 10.1113\/expphysiol.2012.068338","DOI":"10.1113\/expphysiol.2012.068338"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"De La Serna AR, Soldevila JG, Claramunt VM, De Luna AB. Colchicine for recurrent pericarditis. The Lancet. 1987;330(8574):1517. DOI: 10.1016\/S0140-6736(87)92641-9","DOI":"10.1016\/S0140-6736(87)92641-9"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Schulz-Menger J, Collini V, Gr\u00f6schel J, Adler Y, Brucato A, Christian V et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. European Heart Journal. 2025;46(40):3952\u20134041. DOI: 10.1093\/eurheartj\/ehaf192","DOI":"10.1093\/eurheartj\/ehaf192"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Sukmarova Z.N., Saidova M.A., Ovchinnikov Yu.V. Effusive pericarditis in the pathogenesis of cardiac arrhythmias in COVID-19: a case series. Cardiovascular Therapy and Prevention. 2021;21(2):72\u20139. DOI: 10.15829\/1728-8800-2022-3021","DOI":"10.15829\/1728-8800-2022-3021"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Zuin M, Rigatelli G, Bilato C, Imazio M, Roncon L. Autoptic prevalence of pericarditis in coronavirus disease 2019 patients. Journal of Cardiovascular Medicine. 2022;23(9):623\u20135. DOI: 10.2459\/JCM.0000000000001306","DOI":"10.2459\/JCM.0000000000001306"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Ramadan MS, Bertolino L, Zampino R, Durante-Mangoni E, Iossa D, Bertolino L et al. Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review. Clinical Microbiology and Infection. 2021;27(9):1250\u201361. DOI: 10.1016\/j.cmi.2021.06.015","DOI":"10.1016\/j.cmi.2021.06.015"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Sukmarova Z.N., Simonenko V.B., Nasonov E.L. Therapy of pericarditis with colchicine, interleukin-1 antagonists, immunosuppressants. Clinical Medicine (Russian Journal). 2023;101(1):6\u201317. DOI: 10.30629\/0023-2149-2023-101-1-6-17","DOI":"10.30629\/0023-2149-2023-101-1-6-17"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Andreis A, Imazio M, Giustetto C, Brucato A, Adler Y, De Ferrari GM. Anakinra for constrictive pericarditis associated with incessant or recurrent pericarditis. Heart. 2020;106(20):1561\u20135. DOI: 10.1136\/heartjnl-2020-316898","DOI":"10.1136\/heartjnl-2020-316898"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Imazio M, Battaglia A, Gaido L, Gaita F. Recurrent pericarditis. La Revue de M\u00e9decine Interne. 2017;38(5):307\u201311. DOI: 10.1016\/j.revmed.2016.12.006","DOI":"10.1016\/j.revmed.2016.12.006"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Imazio M, Brucato A, Belli R, Forno D, Ferro S, Trinchero R et al. Colchicine for the prevention of pericarditis: what we know and what we do not know in 2014 \u2013 systematic review and meta-analysis. Journal of Cardiovascular Medicine. 2014;15(12):840\u20136. DOI: 10.2459\/JCM.0000000000000103","DOI":"10.2459\/JCM.0000000000000103"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Yadav R, Satti DI, Malwankar J, Lopez-Silva C, Xu L, Liebow-Feeser E et al. Pericarditis After Catheter Ablation for Atrial Fibrillation. JACC: Clinical Electrophysiology. 2024;10(2):262\u20139. DOI: 10.1016\/j.jacep.2023.09.026","DOI":"10.1016\/j.jacep.2023.09.026"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Yakut I, Konte HC, Ozeke O. Exploring Inflammatory Markers and Risk Factors Associated with Pericarditis Development after Ablation for Atrial Fibrillation. Journal of Clinical Medicine. 2024;13(19):5934. DOI: 10.3390\/jcm13195934","DOI":"10.3390\/jcm13195934"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Meurin P, Lelay-Kubas S, Pierre B, Pereira H, Pavy B, Iliou MC et al. Colchicine for postoperative pericardial effusion: a multicentre, double-blind, randomised controlled trial. Heart. 2015;101(21):1711\u20136. DOI: 10.1136\/heartjnl-2015-307827","DOI":"10.1136\/heartjnl-2015-307827"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Benz AP, Amit G, Connolly SJ, Singh J, Acosta-V\u00e9lez JG, Conen D et al. Colchicine to Prevent Atrial Fibrillation Recurrence After Cathet er Ablation: A Randomized, Placebo-Controlled Trial. Circulation: Arrhythmia and Electrophysiology. 2024;17(1):e01238. DOI: 10.1161\/CIRCEP.123.012387","DOI":"10.1161\/CIRCEP.123.012387"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Borra V, Mahadevan A, Gautam Senapati S, Vempati R, Jaiswal V, Borra N et al. The efficacy of colchicine in preventing atrial fibrillation recurrence and pericarditis post-catheter ablation for atrial fibrillation \u2013 A systematic review and meta-analysis of prospective studies. IJC Heart & Vasculature. 2024;53:101466. DOI: 10.1016\/j.ij-cha.2024.101466","DOI":"10.1016\/j.ijcha.2024.101466"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Imazio M, Brucato A, Markel G, Cemin R, Trinchero R, Spodick DH et al. Meta-Analysis of Randomized Trials Focusing on Prevention of the Postpericardiotomy Syndrome. The American Journal of Cardiology. 2011;108(4):575\u20139. DOI: 10.1016\/j.amjcard.2011.03.087","DOI":"10.1016\/j.amjcard.2011.03.087"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Imazio M., Sukmarova Z.N., Nasonov E.L. Complex Issues in the Management of Pericarditis. In Anticipation of the Release of Updated Recommendations of the European Society of Cardiology. Kardiologiia. 2024;64(10):57\u201361. DOI: 10.18087\/cardio.2024.10.n2738","DOI":"10.18087\/cardio.2024.10.n2738"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Morel N, Bonjour M, Le Guern V, Le Jeunne C, Mouthon L, Piette J-C et al. Colchicine: a simple and effective treatment for pericarditis in systemic lupus erythematosus? A report of 10 cases. Lupus. 2015;24(14):1479\u201385. DOI: 10.1177\/0961203315593169","DOI":"10.1177\/0961203315593169"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Alsabri M, Elsayed SM, Elsnhory AB, Abouelmagd K, Ayyad M, Alqeeq BF et al. Efficacy and Safety of Colchicine in Pediatric Pericarditis: A Systematic Review and Future Directions. Pediatric Cardiology. 2025;46(7):1790\u2013805. DOI: 10.1007\/s00246-024-03606-6","DOI":"10.1007\/s00246-024-03606-6"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Somani N, Breur H. The Efficacy of Corticosteroids, NSAIDs, and Colchicine in the Treatment of Pediatric Postoperative Pericardial Effusion. Pediatric Cardiology. 2022;43(2):279\u201389. DOI: 10.1007\/s00246-022-02820-4","DOI":"10.1007\/s00246-022-02820-4"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Lutschinger LL, Rigopoulos AG, Schlattmann P, Matiakis M, Sedding D, Schulze PC et al. Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome. BMC Cardiovascular Disorders. 2019;19(1):207. DOI: 10.1186\/s12872-019-1190-4","DOI":"10.1186\/s12872-019-1190-4"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Libby P, Ridker PM, Maseri A. Inflammation and Atherosclerosis. Circulation. 2002;105(9):1135\u201343. DOI: 10.1161\/hc0902.104353","DOI":"10.1161\/hc0902.104353"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Libby P, Loscalzo J, Ridker PM, Farkouh ME, Hsue PY, Fuster V et al. Inflammation, Immunity, and Infection in Atherothrombosis. Journal of the American College of Cardiology. 2018;72(17):2071\u201381. DOI: 10.1016\/j.jacc.2018.08.1043","DOI":"10.1016\/j.jacc.2018.08.1043"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circulation Research. 2016;118(1):145\u201356. DOI: 10.1161\/CIRCRESAHA.115.306656","DOI":"10.1161\/CIRCRESAHA.115.306656"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine. 2017;377(12):1119\u201331. DOI: 10.1056\/NEJMoa1707914","DOI":"10.1056\/NEJMoa1707914"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Gager GM, Biesinger B, Hofer F, Winter M-P, Hengstenberg C, Jilma B et al. Interleukin-6 level is a powerful predictor of long-term cardiovascular mortality in patients with acute coronary syndrome. Vascular Pharmacology. 2020;135:106806. DOI: 10.1016\/j.vph.2020.106806","DOI":"10.1016\/j.vph.2020.106806"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Khan MS, Talha KM, Maqsood MH, Rymer JA, Borlaug BA, Docherty KF et al. Interleukin-6 and Cardiovascular Events in Healthy Adults. JACC: Advances. 2024;3(8):101063. DOI: 10.1016\/j.jacadv.2024.101063","DOI":"10.1016\/j.jacadv.2024.101063"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Pan Z, Cheng J, Yang W, Chen L, Wang J. Effect of colchicine on inflammatory markers in patients with coronary artery disease: A meta-analysis of clinical trials. European Journal of Pharmacology. 2022;927:175068. DOI: 10.1016\/j.ejphar.2022.175068","DOI":"10.1016\/j.ejphar.2022.175068"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Sun M, Dub\u00e9 M-P, Hennessy T, Schultz CJ, Barhdadi A, Rhainds D et al. Low-dose colchicine and high-sensitivity C-reactive protein after myocardial infarction: A combined analysis using individual patient data from the COLCOT and LoDoCo-MI studies. International Journal of Cardiology. 2022;363:20\u20132. DOI: 10.1016\/j.ijcard.2022.06.028","DOI":"10.1016\/j.ijcard.2022.06.028"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Alam M, Kontopantelis E, Mamas MA, Savinova OV, Jhaveri A, Siddiqui E et al. Meta-analysis of the effect of colchicine on C-reactive protein in patients with acute and chronic coronary syndromes. Coronary Artery Disease. 2023;34(3):210\u20135. DOI: 10.1097\/MCA.0000000000001220","DOI":"10.1097\/MCA.0000000000001220"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Matter MA, Paneni F, Libby P, Frantz S, St\u00e4hli BE, Templin C et al. Inflammation in acute myocardial infarction: the good, the bad and the ugly. European Heart Journal. 2024;45(2):89\u2013103. DOI: 10.1093\/eurheartj\/ehad486","DOI":"10.1093\/eurheartj\/ehad486"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nature Reviews Cardiology. 2014;11(5):255\u201365. DOI: 10.1038\/nrcardio.2014.28","DOI":"10.1038\/nrcardio.2014.28"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Psaltis PJ, Nguyen MT, Singh K, Sinhal A, Wong DTL, Alcock R et al. Optical coherence tomography assessment of the impact of colchicine on nonculprit coronary plaque composition after myocardial infarction. Cardiovascular Research. 2025;121(3):468\u201378. DOI: 10.1093\/cvr\/cvae191","DOI":"10.1093\/cvr\/cvae191"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Yu M, Yang Y, Dong S-L, Zhao C, Yang F, Yuan Y-F et al. Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial. Circulation. 2024;150(13):981\u201393. DOI: 10.1161\/CIRCULATIONAHA.124.069808","DOI":"10.1161\/CIRCULATIONAHA.124.069808"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Vaidya K, Arnott C, Mart\u00ednez GJ, Ng B, McCormack S, Sullivan DR et al. Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome. JACC: Cardiovascular Imaging. 2018;11(2 Pt 2):305\u201316. DOI: 10.1016\/j.jcmg.2017.08.013","DOI":"10.1016\/j.jcmg.2017.08.013"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Mastrocola R, Penna C, Tullio F, Femmin\u00f2 S, Nigro D, Chiazza F et al. Pharmacological Inhibition of NLRP3 Inflammasome Attenuates Myocardial Ischemia\/Reperfusion Injury by Activation of RISK and Mitochondrial Pathways. Oxidative Medicine and Cellular Longevity. 2016;2016(1):5271251. DOI: 10.1155\/2016\/5271251","DOI":"10.1155\/2016\/5271251"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease. Journal of the American College of Cardiology. 2013;61(4):404\u201310. DOI: 10.1016\/j.jacc.2012.10.027","DOI":"10.1016\/j.jacc.2012.10.027"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ et al. Colchicine in Patients with Chronic Coronary Disease. New England Journal of Medicine. 2020;383(19):1838\u201347. DOI: 10.1056\/NEJMoa2021372","DOI":"10.1056\/NEJMoa2021372"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Tardif J-C, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. New England Journal of Medicine. 2019;381(26):2497\u2013505. DOI: 10.1056\/NEJMoa1912388","DOI":"10.1056\/NEJMoa1912388"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Tong DC, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H et al. Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. Circulation. 2020;142(20):1890\u2013900. DOI: 10.1161\/CIRCULATIONAHA.120.050771","DOI":"10.1161\/CIRCULATIONAHA.120.050771"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Tong DC, Bloom JE, Quinn S, Nasis A, Hiew C, Roberts-Thomson P et al. Colchicine in Patients With Acute Coronary Syndrome: TwoYear Follow-Up of the Australian COPS Randomized Clinical Trial. Circulation. 2021;144(19):1584\u20136. DOI: 10.1161\/CIRCULATIONAHA.121.054610","DOI":"10.1161\/CIRCULATIONAHA.121.054610"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Akrami M, Izadpanah P, Bazrafshan M, Hatamipour U, Nouraein N, Drissi HB et al. Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial. BMC Cardiovascular Disorders. 2021;21(1):583. DOI: 10.1186\/s12872-021-02393-9","DOI":"10.1186\/s12872-021-02393-9"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Yousefzadeh M, Khosrobeigi A, Salehi A. Studying the efficacy of low-dose colchicine on clinical outcomes of patients with STEMI: a randomized controlled trial. The Egyptian Heart Journal. 2024;76(1):85. DOI: 10.1186\/s43044-024-00515-0","DOI":"10.1186\/s43044-024-00515-0"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Jolly SS, d\u2019Entremont M-A, Lee SF, Mian R, Tyrwhitt J, Kedev S et al. Colchicine in Acute Myocardial Infarction. New England Journal of Medicine. 2025;392(7):633\u201342. DOI: 10.1056\/NEJMoa2405922","DOI":"10.1056\/NEJMoa2405922"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"O\u2019Keefe JH, McCallister BD, Bateman TM, Kuhnlein DL, Ligon RW, Hartzler GO. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. Journal of the American College of Cardiology. 1992;19(7):1597\u2013600. DOI: 10.1016\/0735-1097(92)90624-V","DOI":"10.1016\/0735-1097(92)90624-V"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Cole J, Htun N, Lew R, Freilich M, Quinn S, Layland J. Colchicine to Prevent Periprocedural Myocardial Injury in Percutaneous Coronary Intervention: The COPE-PCI Pilot Trial. Circulation: Cardiovascular Interventions. 2021;14(5):e009992. DOI: 10.1161\/CIRCINTERVENTIONS.120.009992","DOI":"10.1161\/CIRCINTERVENTIONS.120.009992"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Shah B, Smilowitz NR, Xia Y, Feit F, Katz SD, Zhong J et al. Major Adverse Cardiovascular Events After Colchicine Administration Before Percutaneous Coronary Intervention: Follow-Up of the Colchicine-PCI Trial. The American Journal of Cardiology. 2023;204:26\u20138. DOI: 10.1016\/j.amjcard.2023.07.029","DOI":"10.1016\/j.amjcard.2023.07.029"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Deftereos S, Giannopoulos G, Raisakis K, Kossyvakis C, Kaoukis A, Panagopoulou V et al. Colchicine Treatment for the Prevention of Bare-Metal Stent Restenosis in Diabetic Patients. Journal of the American College of Cardiology. 2013;61(16):1679\u201385. DOI: 10.1016\/j.jacc.2013.01.055","DOI":"10.1016\/j.jacc.2013.01.055"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Opstal TSJ, Nidorf SM, Fiolet ATL, Eikelboom JW, Mosterd A, Bax WA et al. Drivers of mortality in patients with chronic coronary disease in the low-dose colchicine 2 trial. International Journal of Cardiology. 2023;372:1\u20135. DOI: 10.1016\/j.ijcard.2022.12.026","DOI":"10.1016\/j.ijcard.2022.12.026"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Opstal TSJ, Fiolet ATL, Van Broekhoven A, Mosterd A, Eikelboom JW, Nidorf SM et al. Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome. Journal of the American College of Cardiology. 2021;78(9):859\u201366. DOI: 10.1016\/j.jacc.2021.06.037","DOI":"10.1016\/S0735-1097(21)01368-1"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Hennessy T, Soh L, Bowman M, Kurup R, Schultz C, Patel S et al. The Low Dose Colchicine after Myocardial Infarction (LoDoCo-MI) study: A pilot randomized placebo controlled trial of colchicine following acute myocardial infarction. American Heart Journal. 2019;215:62\u20139. DOI: 10.1016\/j.ahj.2019.06.003","DOI":"10.1016\/j.ahj.2019.06.003"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Deftereos S, Giannopoulos G, Angelidis C, Alexopoulos N, Filippatos G, Papoutsidakis N et al. Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study. Circulation. 2015;132(15):1395\u2013403. DOI: 10.1161\/CIRCULATIONAHA.115.017611","DOI":"10.1161\/CIRCULATIONAHA.115.017611"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Mewton N, Roubille F, Bresson D, Prieur C, Bouleti C, Bochaton T et al. Effect of Colchicine on Myocardial Injury in Acute Myocardial Infarction. Circulation. 2021;144(11):859\u201369. DOI: 10.1161\/CIR-CULATIONAHA.121.056177","DOI":"10.1161\/CIRCULATIONAHA.121.056177"},{"key":"ref92","unstructured":"Radwan MA, Sharf EL Din AAER, Mohamed El Etriby SA, Khorshid HM. Colchicine for Preserving Left Ventricular Systolic Function in Patients With STEMI Following Successful Primary PCI: A Speckle-Tracking Echocardiography Study. Iranian Heart Journal. 2024;25(4):84\u201395"},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Hassanain HA, El Wakeel LM, Khorshid H, Ahmed MA. Colchicine effect on biomarkers of cardiac remodelling and atherosclerosis in ST\u2010elevation myocardial infarction: A randomized controlled trial. British Journal of Clinical Pharmacology. 2025;91(2):427\u201338. DOI: 10.1111\/bcp.16270","DOI":"10.1111\/bcp.16270"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Akodad M, Lattuca B, Nagot N, Georgescu V, Buisson M, Cristol J-P et al. COLIN trial: Value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response. Archives of Cardiovascular Diseases. 2017;110(6\u20137):395\u2013402. DOI: 10.1016\/j.acvd.2016.10.004","DOI":"10.1016\/j.acvd.2016.10.004"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Gholoobi A, Askari VR, Naghedinia H, Ahmadi M, Vakili V, Baradaran Rahimi V. Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomised, double-blind, placebo-controlled clinical trial. Inflammopharmacology. 2021;29(5):1379\u201387. DOI: 10.1007\/s10787-021-00865-0","DOI":"10.1007\/s10787-021-00865-0"},{"key":"ref96","doi-asserted-by":"crossref","unstructured":"Ridker PM. Targeting residual inflammatory risk: The next frontier for atherosclerosis treatment and prevention. Vascular Pharmacology. 2023;153:107238. DOI: 10.1016\/j.vph.2023.107238","DOI":"10.1016\/j.vph.2023.107238"},{"key":"ref97","doi-asserted-by":"crossref","unstructured":"Mart\u00ed-Carvajal AJ, Gemmato-Valecillos MA, Monge Mart\u00edn D, De Sanctis JB, Mart\u00ed-Amarista CE, Hidalgo R et al. Colchicine for the primary prevention of cardiovascular events. Cochrane Database of Systematic Reviews. 2025;2025(2):CD015003. DOI: 10.1002\/14651858.CD015003.pub2","DOI":"10.1002\/14651858.CD015003.pub2"},{"key":"ref98","doi-asserted-by":"crossref","unstructured":"Zhou Y, Liu Y, Zeng R, Qiu W, Zhao Y, Zhou Y. Early long-term low-dosage colchicine and major adverse cardiovascular events in patients with acute myocardial infarction: a systematic review and meta-analysis. Frontiers in Cardiovascular Medicine. 2023;10:1194605. DOI: 10.3389\/fcvm.2023.1194605","DOI":"10.3389\/fcvm.2023.1194605"},{"key":"ref99","doi-asserted-by":"crossref","unstructured":"Younas A, Awan Z, Khan T, Mehta S, Munir A, Raja HAA et al. The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trials. Current Problems in Cardiology. 2025;50(1):102878. DOI: 10.1016\/j.cpcardi-ol.2024.102878","DOI":"10.1016\/j.cpcardiol.2024.102878"},{"key":"ref100","doi-asserted-by":"crossref","unstructured":"Naeem F, Tabassum S, Burhan M, Balbaa E, Ibrahim A, Ramadan S et al. Efficacy and safety of colchicine post myocardial infarction: a systematic review, meta-analysis and meta-regression analysis of randomized clinical trials. European Journal of Clinical Pharmacology. 2025;81(9):1257\u201374. DOI: 10.1007\/s00228-025-03869-9","DOI":"10.1007\/s00228-025-03869-9"},{"key":"ref101","doi-asserted-by":"crossref","unstructured":"Chen T, Liu G, Yu B. A meta-analysis evaluating efficacy and safety of colchicine for prevention of major cardiovascular events in patients with coronary artery disease. Clinical Research in Cardiology. 2023;112(11):1487\u2013505. DOI: 10.1007\/s00392-023-02254-9","DOI":"10.1007\/s00392-023-02254-9"},{"key":"ref102","doi-asserted-by":"crossref","unstructured":"Fiolet ATL, Poorthuis MHF, Opstal TSJ, Amarenco P, Boczar KE, Buysschaert I et al. Colchicine for secondary prevention of ischaemic stroke and atherosclerotic events: a meta-analysis of randomised trials. eClinicalMedicine. 2024;76:102835. DOI: 10.1016\/j.eclinm.2024.102835","DOI":"10.1016\/j.eclinm.2024.102835"},{"key":"ref103","doi-asserted-by":"crossref","unstructured":"Samuel M, Berry C, Dub\u00e9 M-P, Koenig W, L\u00f3pez-Send\u00f3n J, Maggioni AP et al. Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis. European Heart Journal. 2025;46(26):2552\u201363. DOI: 10.1093\/eurheartj\/ehaf174","DOI":"10.1093\/eurheartj\/ehaf174"},{"key":"ref104","doi-asserted-by":"crossref","unstructured":"d\u2019Entremont M-A, Poorthuis MHF, Fiolet ATL, Amarenco P, Boczar KE, Buysschaert I et al. Colchicine for secondary prevention of vascular events: a meta-analysis of trials. European Heart Journal. 2025;46(26):2564\u201375. DOI: 10.1093\/eurheartj\/ehaf210","DOI":"10.1093\/eurheartj\/ehaf210"},{"key":"ref105","doi-asserted-by":"crossref","unstructured":"Ballacci F, Giordano F, Conte C, Telesca A, Collini V, Imazio M. Colchicine for prevention of major adverse cardiovascular events: a meta-analysis of randomized clinical trials. Journal of Cardiovascular Medicine. 2025;26(7):359\u201368. DOI: 10.2459\/JCM.0000000000001744","DOI":"10.2459\/JCM.0000000000001744"},{"key":"ref106","doi-asserted-by":"crossref","unstructured":"Samuel M, Tardif J-C, Khairy P, Roubille F, Waters DD, Gr\u00e9goire JC et al. Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). European Heart Journal - Quality of Care and Clinical Outcomes. 2021;7(5):486\u201395. DOI: 10.1093\/ehjqcco\/qcaa045","DOI":"10.1093\/ehjqcco\/qcaa045"},{"key":"ref107","doi-asserted-by":"crossref","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023;44(38):3720\u2013826. DOI: 10.1093\/eurheartj\/ehad191","DOI":"10.1093\/eurheartj\/ehad191"},{"key":"ref108","doi-asserted-by":"crossref","unstructured":"Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. European Heart Journal. 2024;45(36):3415\u2013537. DOI: 10.1093\/eurheartj\/ehae177","DOI":"10.1093\/eurheartj\/ehae177"},{"key":"ref109","doi-asserted-by":"crossref","unstructured":"Herrmann J, Lennon RJ, Barsness GW, Sandhu GS, Gulati R, Best PJM et al. High Sensitivity C-Reactive Protein and Outcomes Following Percutaneous Coronary Intervention in Contemporary Practice. Circulation: Cardiovascular Interventions. 2012;5(6):783\u201390. DOI: 10.1161\/CIRCINTERVENTIONS.112.972182","DOI":"10.1161\/CIRCINTERVENTIONS.112.972182"},{"key":"ref110","doi-asserted-by":"crossref","unstructured":"Shah B, Baber U, Pocock SJ, Krucoff MW, Ariti C, Gibson CM et al. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circulation: Cardiovascular Interventions. 2017;10(9):e004981. DOI: 10.1161\/CIRCINTERVENTIONS.117.004981","DOI":"10.1161\/CIRCINTERVENTIONS.117.004981"},{"key":"ref111","doi-asserted-by":"crossref","unstructured":"Chen A, Lu D, Yang Z, Che X, Xia Y, Shao X et al. Association between NLRP3 inflammasome and periprocedural myocardial injury following elective PCI. Heliyon. 2023;9(8):e19269. DOI: 10.1016\/j.heliyon.2023.e19269","DOI":"10.1016\/j.heliyon.2023.e19269"},{"key":"ref112","doi-asserted-by":"crossref","unstructured":"Shah B, Pillinger M, Zhong H, Cronstein B, Xia Y, Lorin JD et al. Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention: COLCHICINE-PCI Randomized Trial. Circulation: Cardiovascular Interventions. 2020;13(4):e008717. DOI: 10.1161\/CIRCINTERVENTIONS.119.008717","DOI":"10.1161\/CIRCINTERVENTIONS.119.008717"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/viewFile\/3016\/1948","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:16:12Z","timestamp":1793639772000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/3016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,28]]},"references-count":112,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,12,28]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2025.11.n3016","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,28]]}}}